

# Jurgen Vercauteren

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7515166/publications.pdf>

Version: 2024-02-01

42  
papers

2,020  
citations

304368

22  
h-index

276539

41  
g-index

45  
all docs

45  
docs citations

45  
times ranked

3185  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phenotypical and Functional Characterization of Neutrophils in Two Pysin-Associated Auto-inflammatory Diseases. <i>Journal of Clinical Immunology</i> , 2021, 41, 1072-1084.	2.0	6
2	Behavioral changes before lockdown and decreased retail and recreation mobility during lockdown contributed most to controlling COVID-19 in Western countries. <i>BMC Public Health</i> , 2021, 21, 654.	1.2	18
3	Road to Metastasis: The TWEAK Pathway as a Discriminant between Metastasizing and Non-Metastasizing Thick Melanomas. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10568.	1.8	0
4	Global and regional epidemiology of HIV-1 recombinants in 1990–2015: a systematic review and global survey. <i>Lancet HIV</i> , 2020, 7, e772-e781.	2.1	51
5	Global and regional molecular epidemiology of HIV-1, 1990–2015: a systematic review, global survey, and trend analysis. <i>Lancet Infectious Diseases</i> , 2019, 19, 143-155.	4.6	255
6	Predictors of non adherence to antiretroviral therapy at an urban HIV care and treatment center in Tanzania. <i>Drug, Healthcare and Patient Safety</i> , 2018, Volume 10, 79-88.	1.0	18
7	Comprehensive Antiretroviral Restriction Factor Profiling Reveals the Evolutionary Imprint of the ex Vivo and in Vivo IFN- $\gamma$ Response in HTLV-1-Associated Neuroinflammation. <i>Frontiers in Microbiology</i> , 2018, 9, 985.	1.5	12
8	Single- and multiple-dose pharmacokinetics and safety of pimodivir, a novel, non-nucleoside polymerase basic protein 2 subunit inhibitor of the influenza A virus polymerase complex, and interaction with oseltamivir: a Phase 1 open-label study in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2663-2672.	1.1	13
9	A Fashi Lymphoproliferative Phenotype Reveals Non-Apoptotic Fas Signaling in HTLV-1-Associated Neuroinflammation. <i>Frontiers in Immunology</i> , 2017, 8, 97.	2.2	14
10	The global spread of HIV-1 subtype B epidemic. <i>Infection, Genetics and Evolution</i> , 2016, 46, 169-179.	1.0	60
11	Efficacy of tenofovir and efavirenz in combination with lamivudine or emtricitabine in antiretroviral-naïve patients in Europe. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1850-7.	1.3	12
12	CRF19_cpx is an Evolutionary fit HIV-1 Variant Strongly Associated With Rapid Progression to AIDS in Cuba. <i>EBioMedicine</i> , 2015, 2, 244-254.	2.7	56
13	Global Dispersal Pattern of HIV Type 1 Subtype CRF01_AE: A Genetic Trace of Human Mobility Related to Heterosexual Sexual Activities Centralized in Southeast Asia. <i>Journal of Infectious Diseases</i> , 2015, 211, 1735-1744.	1.9	62
14	Trends and Predictors of Transmitted Drug Resistance (TDR) and Clusters with TDR in a Local Belgian HIV-1 Epidemic. <i>PLoS ONE</i> , 2014, 9, e101738.	1.1	36
15	Pharmacy refill adherence outperforms self-reported methods in predicting HIV therapy outcome in resource-limited settings. <i>BMC Public Health</i> , 2014, 14, 1035.	1.2	82
16	Clinical and virological response to antiretroviral drugs among HIV patients on first-line treatment in Dar-es-Salaam, Tanzania. <i>Journal of Infection in Developing Countries</i> , 2014, 8, 845-852.	0.5	8
17	Higher proportion of G2P[4] rotaviruses in vaccinated hospitalized cases compared with unvaccinated hospitalized cases, despite high vaccine effectiveness against heterotypic G2P[4] rotaviruses. <i>Clinical Microbiology and Infection</i> , 2014, 20, O702-O710.	2.8	50
18	Evolutionary analysis of HBV $\alpha$ -antigen genetic diversity in Iranian blood donors: A nationwide study. <i>Journal of Medical Virology</i> , 2014, 86, 144-155.	2.5	28

#	ARTICLE	IF	CITATIONS
19	Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe. <i>BMC Infectious Diseases</i> , 2014, 14, 407.	1.3	43
20	Patterns of Transmitted HIV Drug Resistance in Europe Vary by Risk Group. <i>PLoS ONE</i> , 2014, 9, e94495.	1.1	32
21	HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics. <i>Retrovirology</i> , 2013, 10, 7.	0.9	129
22	Gender differences in HIV disease progression and treatment outcomes among HIV patients one year after starting antiretroviral treatment (ART) in Dar es Salaam, Tanzania. <i>BMC Public Health</i> , 2013, 13, 38.	1.2	58
23	HIV-1 fitness landscape models for indinavir treatment pressure using observed evolution in longitudinal sequence data are predictive for treatment failure. <i>Infection, Genetics and Evolution</i> , 2013, 19, 349-360.	1.0	4
24	Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 419-423.	1.3	4
25	The demise of multidrug-resistant HIV-1: the national time trend in Portugal. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 911-914.	1.3	6
26	HIV-1 Subtype Is an Independent Predictor of Reverse Transcriptase Mutation K65R in HIV-1 Patients Treated with Combination Antiretroviral Therapy Including Tenofovir. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1053-1056.	1.4	39
27	Clinical Evaluation of Rega 8: An Updated Genotypic Interpretation System That Significantly Predicts HIV-Therapy Response. <i>PLoS ONE</i> , 2013, 8, e61436.	1.1	17
28	Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naïve HIV-1 infected patients. <i>Retrovirology</i> , 2012, 9, 81.	0.9	23
29	HIV-1 transmitted drug resistance in Latin America and the Caribbean: what do we know?. <i>AIDS Reviews</i> , 2012, 14, 256-67.	0.5	8
30	Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials. <i>Supportive Care in Cancer</i> , 2011, 19, 1753-1760.	1.0	133
31	Examining the relationships among health-related quality-of-life indicators in cancer patients participating in clinical trials: a pooled study of baseline EORTC QLQ-C30 data. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2011, 11, 587-599.	0.7	12
32	Effect of human immunodeficiency virus type 1 protease inhibitor therapy and subtype on development of resistance in subtypes B and G. <i>Infection, Genetics and Evolution</i> , 2010, 10, 373-379.	1.0	9
33	Cellular HIV-1 DNA Levels in Drug Sensitive Strains Are Equivalent to Those in Drug Resistant Strains in Newly-Diagnosed Patients in Europe. <i>PLoS ONE</i> , 2010, 5, e10976.	1.1	10
34	Transmission of Drug-Resistant HIV-1 Is Stabilizing in Europe. <i>Journal of Infectious Diseases</i> , 2009, 200, 1503-1508.	1.9	213
35	Relating increasing hantavirus incidences to the changing climate: the mast connection. <i>International Journal of Health Geographics</i> , 2009, 8, 1.	1.2	198
36	The rise and fall of K65R in a Portuguese HIV-1 Drug Resistance database, despite continuously increasing use of tenofovir. <i>Infection, Genetics and Evolution</i> , 2009, 9, 683-688.	1.0	8

#	ARTICLE	IF	CITATIONS
37	Investigation of expert rule bases, logistic regression, and non-linear machine learning techniques for predicting response to antiretroviral treatment. <i>Antiviral Therapy</i> , 2009, 14, 433-442.	0.6	19
38	Investigation of expert rule bases, logistic regression, and non-linear machine learning techniques for predicting response to antiretroviral treatment. <i>Antiviral Therapy</i> , 2009, 14, 433-442.	0.6	35
39	The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal. <i>Retrovirology</i> , 2008, 5, 12.	0.9	43
40	Prevalence and Epidemiology of HIV Type 1 Drug Resistance among Newly Diagnosed Therapy-Naive Patients in Belgium from 2003 to 2006. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 355-362.	0.5	33
41	Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. <i>Aids</i> , 2008, 22, 625-635.	1.0	109
42	Algorithms for the interpretation of HIV-1 genotypic drug resistance information. <i>Antiviral Research</i> , 2006, 71, 335-342.	1.9	54